The first Ebola vaccine has been administered to 20 healthy adults in clinical trials in the United States, researchers.
The trial vaccine was developed through collaboration of the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, and Okairos, a Swiss-Italian biotech company recently acquired by the pharmaceutical company GlaxoSmithKline, German Press Agency dpa reported.
The vaccine was first successfully tested on monkeys ahead of the 48-week trial on human participants between the ages of 18 and 50.
There is no danger that the participants can become infected with the disease, NIAID said.